Adlyxin (Lixisenatide) 100 mcg / ml
Adlyxin, also known as lixisenatide, is a daily injectable prescription medication. It is used in adults with type 2 diabetes mellitus (T2DM) to better glycemic control in addition to diet and exercise. Controlling hyperglycemia with Adlyxin prevents downstream complications such as kidney damage, limb loss, heart attack, blindness, stroke, or nerve problems. It is important that diabetes remains controlled to lessen the chance of related complications. Adlyxin is provided as a single-patient-use prefilled pen.
Limitations of Use:
Adlyxin has not been evaluated in patients with pancreatitis or a history of pancreatitis
Adlyxin is not indicated for those with type 1 diabetes mellitus (T1DM)
Adlyxin has not been evaluated in those with gastroparesis and is therefore not recommended in these patients
HOW DOES ADLYXIN WORK?
Incretins are peptide hormones originating from the gut that are quickly released after a meal. The two primary incretins in humans include glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1). Incretins such as GLP-1 potentiate glucose-dependent insulin release and exert multiple antihyperglycemic effects after their secretion from the gut into the circulation.
Adlyxin is a GLP-1 receptor agonist that elevates glucose-dependent insulin release by
pancreatic beta-cells, lessening abnormally elevated glucagon release and decreasing gastric emptying. Through this mechanism, it improves glycemic control in patients with type 2 diabetes.
Common side effects associated with Adlyxin include:
Gastrointestinal symptoms (e.g. nausea, vomiting, and diarrhea)
Injection site reactions such as pain, erythema, and pruritus